T. Rowe Price Investment Management, Inc. Replimune Group, Inc. Transaction History

T. Rowe Price Investment Management, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$15.65 - $24.1 $7.86 Million - $12.1 Million	-502,531 Reduced 40.85%	727,610 $16.9 Million
Q1 2023 May 15, 2023	SELL	$17.48 - $29.09 $114,948 - $191,295	-6,576 Reduced 0.53%	1,230,141 $21.7 Million
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $168,285 - $274,829	9,847 Added 0.8%	1,236,717 $33.6 Million
Q3 2022 Nov 14, 2022	BUY	$15.6 - $21.15 $19.1 Million - $25.9 Million	1,226,870 New	1,226,870 $21.2 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $631M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.